Another study reported the fusion of CD19 scFv to CD3 subunits could utilize antigen-specific activation of TCR signaling, while scFv-CD3ε engineered T cells showed better anti-tumor efficacy than CAR-T [16]. This evidence concerns the gene CD19 and neoplasm.